Deep Track Capital

200 Greenwich Avenue
Greenwich, CT 6830

Website: deeptrackcapital.com

Firm Size

  • Assets Under Management (AUM):$5.1 Billion
  • Number of Funds:1
  • Employees:19
  • Firm Type:Hedge Fund


Description

Deep Track Capital, LP is a Greenwich, CT based private investment firm that specializes in the transportation sector. They primarily focus on providing growth capital and strategic guidance to companies operating in the rail, maritime, and logistics industries. Deep Track Capital aims to identify investment opportunities that have the potential to generate attractive returns while also making a positive impact on the environment and society. The firm's investment approach involves partnering with companies that offer innovative solutions to the challenges within the transportation sector, such as reducing emissions, enhancing operational efficiency, and improving safety standards. They strive to invest in businesses that demonstrate strong growth potential and have a clear competitive advantage in their respective markets. Deep Track Capital's team consists of experienced professionals with deep industry expertise in transportation, finance, and sustainability. They work closely with their portfolio companies to provide strategic advice, operational support, and access to their extensive network of industry contacts. By leveraging their knowledge and industry relationships, the firm aims to help their portfolio companies achieve their growth objectives and create long-term value. Overall, Deep Track Capital, LP is committed to driving positive change in the transportation sector by supporting innovative companies and initiatives that have the potential to significantly impact the industry's sustainability and economic efficiency.

Latest News

Powered by

Apr 10, 2024: TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline


Mar 18, 2024: Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Adage Capital Partners LP, Avidity Partners, Boxer Capital, Darwin Global Management, Deep Track Capital, funds affiliated with Farallon Capital Management, L.L.C., Logos Capital, Perceptive Advisors, RTW Investments, a leading biotechnology investor associated with one of the largest alternative asset managers, and a large investment management firm.

Mar 12, 2024: Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Partners L.P., Deep Track Capital, the Federated Hermes Kaufmann Funds, New Enterprise Associates (NEA), Octagon Capital, RA Capital Management, and Vivo Capital. Upon the closing of the financing, which is anticipated to occur on or about March 14, 2024, the Company expects to receive gross proceeds of approximately $100 million . The closing of the financing is subject to customary closing conditions.

Apr 13, 2023: TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics